Seeing Is Believing
Currently out of the existing stock ratings of Josh Schimmer, 97 are a BUY (87.39%), 13 are a HOLD (11.71%), 1 are a SELL (0.9%).
Analyst Josh Schimmer, currently employed at CANTOR FITZGERALD, carries an average stock price target met ratio of 52.24% that have a potential upside of 46.86% achieved within 268 days. Previously, Josh Schimmer worked at EVERCORE.
Josh Schimmer’s has documented 564 price targets and ratings displayed on 31 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on KRYS, Krystal Biotech at 29-Aug-2024.
Analyst best performing recommendations are on SPRO (SPERO THERAPEUTICS).
The best stock recommendation documented was for SPRO (SPERO THERAPEUTICS) at 5/4/2022. The price target of $2 was fulfilled within 2 days with a profit of $0.25 (14.29%) receiving and performance score of 71.43.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
205
$22.5 (12.33%)
3 years 3 months 26 days ago
3/5 (60%)
$35.09 (20.65%)
938
Hold
173
$-9.5 (-5.21%)
156
3 years 3 months 28 days ago
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
190
$7.5 (4.11%)
194
3 years 6 months 27 days ago
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
166
$-16.5 (-9.04%)
175
3 years 6 months 27 days ago
23/23 (100%)
$10.41 (6.69%)
828
Buy
155
3 years 7 months 24 days ago
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Josh Schimmer is most bullish on?
Which stock is Josh Schimmer is most reserved on?
What Year was the first public recommendation made by Josh Schimmer?